{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:03:41Z","timestamp":1790233421857,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T00:00:00Z","timestamp":1475020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Genentech and by the Weill Cornell Medical College Clinical and Translational Science Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Interleukin\u20106 (IL\u20106) is a pivotal cytokine in the pathogenesis of polymyalgia rheumatica (PMR), yet the efficacy of IL\u20106 blockade with tocilizumab (TCZ) for the treatment of PMR is unknown. The aim of this study was to assess the efficacy and safety of TCZ in newly diagnosed PMR.<\/jats:p><jats:p>M<jats:italic>ethods<\/jats:italic>. In a single\u2010center open\u2010label study, patients with newly diagnosed PMR who had been treated with glucocorticoids (GCs) for &lt;1 month were treated monthly with intravenous (IV) TCZ 8\u2009mg\/kg for 1 year, with a rapid tapering of GCs according to standardized protocol. The primary end point was the proportion of patients in relapse\u2010free remission without GC treatment at 6 months. Secondary outcome measures included duration of GC use and cumulative GC dose. Patients were followed up for 15 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten patients were enrolled in the study. One patient withdrew after 2 months, leaving 9 patients in whom the primary end point was assessed. The primary end point of relapse\u2010free remission without GC treatment at 6 months was achieved by all 9 of these patients. All patients who received TCZ treatment were able to discontinue GCs within 4 months of study entry. The cumulative mean\u2009\u00b1\u2009SD prednisone dose was 1,085\u2009\u00b1\u2009301 mg and the total duration of GC exposure was 3.9\u2009\u00b1\u20090.9 months. Remission persisted without relapse, in all 9 patients, throughout the entire 15\u2010month study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggest that TCZ may be an effective, safe, and well\u2010tolerated treatment for newly diagnosed patients with PMR, with a robust steroid\u2010sparing effect.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.39740","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T15:54:31Z","timestamp":1462809271000},"page":"2550-2554","source":"Crossref","is-referenced-by-count":109,"title":["Brief Report: A Prospective Open\u2010Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica"],"prefix":"10.1002","volume":"68","author":[{"given":"Lindsay","family":"Lally","sequence":"first","affiliation":[{"name":"Hospital for Special Surgery New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsy","family":"Forbess","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hatzis","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Spiera","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20901"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401022"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/29.6.456"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360913"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23924"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091185"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21750"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.01.003"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182a6aa0e"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(84)90012-X"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34356"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.011379"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00005"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208742"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2650-y"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.4.218"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-7-200410050-00005"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207578"},{"key":"e_1_2_8_21_1","first-page":"395","article-title":"Long\u2010term follow\u2010up of polymyalgia rheumatica patients treated with methotrexate and steroids","volume":"26","author":"Cimmino MA","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_22_1","article-title":"Tocilizumab enhances regulatory T\u2010cell activation and proliferation in giant cell arteritis [abstract]","author":"Miyabe C","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.39740","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.39740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:13:45Z","timestamp":1759940025000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.39740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1002\/art.39740"],"URL":"https:\/\/doi.org\/10.1002\/art.39740","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]}}}